Skip to Content

Atropine / pralidoxime Pregnancy and Breastfeeding Warnings

Atropine / pralidoxime is also known as: ATNAA, DuoDote

Medically reviewed on Apr 9, 2018

Atropine / pralidoxime Pregnancy Warnings

Animal studies have not been conducted on either active ingredient or the combination. There are no controlled data in human pregnancy. Atropine readily crosses the placenta and enters fetal circulation. It is unknown if they cause fetal harm or affect reproductive capacity.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Use is recommended only if clearly needed.

US FDA pregnancy category: C

See references

Atropine / pralidoxime Breastfeeding Warnings

Caution is recommended.

Excreted into human milk: Yes

Comments:
-Atropine is excreted in human milk; it is unknown if pralidoxime is excreted in human milk.
-There are no data on the effects of atropine on the breastfed infant or on milk production.

See references

References for pregnancy information

  1. "Product Information. DuoDote (atropine-pralidoxime)." Meridian Medical Technologies Inc, Columbia, MD.
  2. "Product Information. ATNAA (atropine-pralidoxime)." Meridian Medical Technologies Inc, Columbia, MD.

References for breastfeeding information

  1. "Product Information. ATNAA (atropine-pralidoxime)." Meridian Medical Technologies Inc, Columbia, MD.
  2. "Product Information. DuoDote (atropine-pralidoxime)." Meridian Medical Technologies Inc, Columbia, MD.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide